Clinical trial
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
NCT05237713 is registered in ClinicalTrials.gov with University of Leipzig as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
- Lead sponsor
- University of Leipzig
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 26, 2022
- Completion date
- February 29, 2024
- Enrollment
- 10 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.